Amid outcry, KaloBios may jack the drug’s price and make millions off FDA voucher.
Source: In comeback bid, Shkreli’s old company gets OK to buy life-saving drug | Ars Technica
After firing indicted CEO, company now fights to keep shares listed on NASDAQ.
Source: Martin Shkreli’s other pharma company files for bankruptcy | Ars Technica
Following arrest of CEO, KaloBios loses CFO, accountants, is delisted from Nasdaq.
Source: Martin Shkreli’s other pharma company is dramatically collapsing | Ars Technica